Skip to content

Study · Not a test of the peptide alone · 2011

1 result

Structural insight into the role of the human melanocortin 3 receptor cysteine residues on receptor function.

Yang Y, Chen M, McPherson D, Mishra V, Harmon CM

Peptides31 Oct 2011Cited by 3 (Europe PMC)

PMID22079958 (opens in a new tab)PMCIDPMC3242444 (opens in a new tab)DOI10.1016/j.peptides.2011.09.024 (opens in a new tab)PepBankPUB-22079958
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 01LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cells)Activity measurement

    In HEK-293 cells, the hMC3R mutations C115S and C162S in transmembrane domain 3 significantly decreased the binding affinity and potency of NDP-MSH.

    In plain wordsIn cells, two changes in the MC3R receptor lowered how tightly and strongly the NDP-MSH peptide acted on it.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseNDP-MSH binding affinity and potency at C115S and C162S hMC3R mutants
    Study

    humann: not reported in source

    HEK-293 cells expressing cysteine-to-serine hMC3R mutants
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    two other mutations C115S and C162S in TM3 significantly decreased NDP-MSH binding affinity and potency.
    1 context sentence
    Summary · context
    We replaced these cysteines with serine and expressed these receptors in HEK-293 cells which lack endogenous MC3R.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.